Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1143 | Topotecan | Topo I | Chemotherapy | 0.0094142 | -0.4304 | 0.9040 | 0.3002 | 1.1711 | 0.013874 | 0.94725 |
HCC1954 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.014251 | -0.0830 | 0.5651 | 0.1455 | 1.3479 | 0.013876 | 0.98856 |
BT-549 | Dinaciclib | pan CDK | Cell cycle | 0.012371 | -0.2923 | 0.5913 | 0.1485 | 3.7837 | 0.013904 | 0.99899 |
PDX1258 | Doxorubicin | Chemo | Chemotherapy | 0.0091389 | -0.4928 | 0.7540 | 0.2368 | 1.1844 | 0.013938 | 0.97567 |
MDA-MB-453 | AZD7762 | CHK1/2 | Cell cycle | 0.011509 | -0.2157 | 0.8564 | 0.1405 | 1.6714 | 0.014102 | 0.99393 |
HCC70 | Doxorubicin | Chemo | Chemotherapy | 0.010621 | -0.7794 | 0.7867 | 0.1459 | 2.0410 | 0.014138 | 0.93856 |
SUM149PT | Volasertib | PLK | Cell cycle | 0.011968 | -0.3041 | 0.5727 | 0.2215 | 2.4715 | 0.014187 | 0.99692 |
CAL-51 | Doxorubicin | Chemo | Chemotherapy | 0.0085841 | -0.4803 | 0.7954 | 0.2347 | 1.0881 | 0.014188 | 0.98761 |
PDX1258 | Dinaciclib | pan CDK | Cell cycle | 0.011566 | -0.6173 | 0.7036 | 0.2838 | 3.5943 | 0.014366 | 0.99779 |
MCF7 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0083619 | -0.2545 | 0.7677 | 0.1823 | 0.5107 | 0.014367 | 0.95432 |
SUM159PT | INK-128 | mTORC1/2 | PI3K/mTOR | 0.018735 | 0.1504 | 0.4832 | 0.0004 | 1.5649 | 0.014424 | 0.99839 |
MDA-MB-361 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0050713 | -0.9642 | 0.8689 | 0.2561 | 0.9911 | 0.014575 | 0.99687 |
BT-549 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.016573 | 0.0717 | 0.5339 | 0.0484 | 1.5295 | 0.014683 | 0.99934 |
PDX1328 | Dinaciclib | pan CDK | Cell cycle | 0.011496 | -0.7107 | 0.7519 | 0.2292 | 3.5560 | 0.014708 | 0.9982 |
HCC38 | Dinaciclib | pan CDK | Cell cycle | 0.012678 | -0.4422 | 0.6326 | 0.2241 | 4.1199 | 0.014763 | 0.99821 |
MDA-MB-436 | Dinaciclib | pan CDK | Cell cycle | 0.014324 | -0.1440 | 0.4903 | 0.0235 | 4.8527 | 0.014993 | 0.99777 |
MDA-MB-231 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.021834 | 0.1013 | 0.4860 | 0.0253 | 1.0516 | 0.015209 | 0.98917 |
HCC1954 | Dinaciclib | pan CDK | Cell cycle | 0.012538 | -0.4640 | 0.6411 | 0.3049 | 3.3292 | 0.015238 | 0.99808 |
PDXHCI002 | Topotecan | Topo I | Chemotherapy | 0.0066461 | -0.7006 | 1.0199 | 0.1157 | 0.8130 | 0.015555 | 0.94766 |
HCC1395 | Dinaciclib | pan CDK | Cell cycle | 0.012405 | -0.4966 | 0.6520 | 0.1554 | 2.9854 | 0.015612 | 0.99791 |
HCC38 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.01047 | -0.2107 | 0.5383 | 0.0927 | 0.8737 | 0.015621 | 0.99367 |
HCC1395 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.014555 | -0.1424 | 0.4547 | 0.0604 | 1.6344 | 0.015746 | 0.98865 |
HCC70 | Dinaciclib | pan CDK | Cell cycle | 0.01286 | -0.9093 | 0.8338 | 0.3254 | 5.0000 | 0.015807 | 0.9991 |
MDA-MB-468 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.016032 | -0.0415 | 0.4371 | 0.1010 | 0.9482 | 0.015849 | 0.98843 |
MDA-MB-134-VI | Dinaciclib | pan CDK | Cell cycle | 0.010529 | -0.8440 | 0.7452 | 0.1522 | 2.1701 | 0.015963 | 0.99365 |